التفاصيل البيبلوغرافية
| العنوان: |
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine |
| المؤلفون: |
PACETTI P, GIOVANNETTI E, MAMBRINI A, NANNIZZI S, ORLANDI M, TARTARINI R, DEL FREO A, DEL TACCA M, DANESI, ROMANO, CANTORE M. |
| المساهمون: |
P. Pacetti, E. Giovannetti, A. Mambrini, S. Nannizzi, M. Orlandi, R. Tartarini, A. DEL FREO, M. DEL TACCA, R. Danesi, M. Cantore |
| سنة النشر: |
2009 |
| المجموعة: |
The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: |
capecitabine, cisplatin, Biliary tract carcinoma |
| الوصف: |
BACKGROUND: Biliary tract carcinoma (BTC) is a rare highly malignant neoplasia. Polymorphisms at the xeroderma pigmentosum group D (XPD), excision repair cross-complementing group-1 (ERCC1) and X-ray repair cross complementing group 1 (XRCC1) genes were evaluated and correlated with clinical outcome. PATIENTS AND METHODS: Thirty-three patients with BTC were treated with intravenous or intra-arterial cisplatin and epirubicin and oral capecitabine. The ERCC1-C118T, XPD-Asp312Asn, XPD-Lys751Gln and XRCC1-Arg399Gln polymorphisms were studied. RESULTS: A partial response (PR) occurred in 6 patients. The median progression-free (PFS) and overall survival (OS) were 4.8 and 18.9 months, respectively. No significant correlations were observed between response, PFS and OS in patients grouped according to all the studied polymorphisms. The analysis of survival starting from diagnosis resulted in a significant association of the XRCC1-Arg399Arg variant with a shorter survival. CONCLUSION: A role of the XRCC1-Arg399Gln polymorphism as a possible prognostic factor in patients affected by BTC is suggested. ; Background: Biliary tract carcinoma (BTC) is a rare highly malignant neoplasia. Polymorphisms at the xeroderma pigmentosum group D (XPD), excision repair cross-complementing group-1 (ERCC1) and X-ray repair cross complementing group 1 (XRCC1) genes were evaluated and correlated with clinical outcome. Patients and Methods: Thirty-three patients with BTC were treated with intravenous or intra-arterial cisplatin and epirubicin and oral capecitabine. The ERCC1-C118T, XPD-Asp312Asn, XPD-Lys751Gln and XRCC1-Arg399Gln polymorphisms were studied. Results: A partial response (PR) occurred in 6 patients. The median progression-free (PFS) and overall survival (OS) were 4.8 and 18.9 months, respectively. No significant correlations were observed between response, PFS and OS in patients grouped according to all the studied polymorphisms. The analysis of survival starting from diagnosis resulted in a significant association of the ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/19443413; info:eu-repo/semantics/altIdentifier/wos/WOS:000267389300083; volume:29; issue:5; firstpage:1835; lastpage:1840; numberofpages:6; journal:ANTICANCER RESEARCH; https://hdl.handle.net/2434/1120904 |
| الاتاحة: |
https://hdl.handle.net/2434/1120904 |
| رقم الانضمام: |
edsbas.B22A2474 |
| قاعدة البيانات: |
BASE |